# A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04478279/  
OnCo record `nct04478279` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in melanoma and prostate cancer, run by Sapience Therapeutics, active and no longer recruiting.

## Summary

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04478279 by Sapience Therapeutics, with 125 participants enrolled, started 2020-07-01 and due to reach its primary completion in 2026-12. Interventions recorded: ST101, Temozolomide, Radiation. Conditions listed: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04478279
- Phase: 1/2
- Setting: A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
- Sponsor: Sapience Therapeutics
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT04478279: https://clinicaltrials.gov/study/NCT04478279

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Melanoma](https://onco.cc/cancers/melanoma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct04478279.json